A new weight loss shot called MariTide is creating buzz after its first trial showed better results than leading drugs like Wegovy and Mounjaro. These medications, designed to control blood sugar in diabetes, are also approved for weight loss in people with obesity or heart risks. MariTide, however, offers something different—a monthly dose that could make managing weight and health easier for those with chronic conditions.
MariTide stands out because it only requires one injection a month, thanks to a monoclonal antibody that keeps it active longer in the body. Weekly shots like Wegovy and Mounjaro can feel overwhelming, especially for diabetes patients already taking daily insulin. Dr. Michelle Ponder, a Duke University expert, said fewer shots can be a huge relief, helping patients stay committed to their treatment without extra stress.
The trial included 600 participants, divided into those with obesity alone and those with both obesity and Type 2 diabetes. They received either one of three MariTide doses or a placebo monthly for a year. The results were striking: people with obesity alone lost up to 20% of their body weight, compared to just 2.6% for the placebo group.
Those with diabetes saw a 17% weight loss with MariTide, while the placebo group dropped only 1.4%. Jay Bradner, a lead researcher at Amgen, said the drug not only sustained weight loss but also improved heart health markers, offering hope for better long-term outcomes. Its monthly dosing could make it easier for patients to stay on track, and larger trials are now in the works.
For anyone living with obesity or diabetes, MariTide’s trial results are a ray of hope. Its convenient dosing and powerful effects could simplify health management and boost confidence. As research moves forward, this monthly shot might become a vital tool for improving lives and building a healthier future.
